LL-37 vs KPV
Side-by-side comparison of LL-37, KPV — mechanism, dosing, half-life, side effects, and research status.
| Attribute | LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery | KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Human Cathelicidin | Alpha-MSH C-terminal Tripeptide |
| Amino acids | 37 | 3 |
| Molecular weight | 4,493.3 Da | 355.4 Da |
| Half-life | Short (hours) | Short (hours) |
| Route(s) | Subcutaneous, Topical, Intranasal | Subcutaneous, Oral (GI conditions), Topical |
| Mechanism & Research | ||
| Primary mechanism | LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan… | KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… |
| Research status | Research Compound | Research Compound |
| Evidence summary | LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it… | KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. |
| Protocol & Dosing | ||
| Typical dose | 1–5 mg per injection or topical application | 500 mcg–2 mg/day (SC); variable oral dosing |
| Frequency | Daily | Once or twice daily |
| Duration | 4–8 weeks | 4–8 weeks |
| Timing | Any time | Any time; pre-meals for GI applications |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | BPC-157, GHK-Cu, KPV | BPC-157, LL-37, TB-500 |
| Full profile | Read full LL-37 profile → | Read full KPV profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.